John J. P. Kastelein

1954 -

country of citizenship: Kingdom of the Netherlands

languages spoken, written or signed: Dutch, English

occupation: physician

award received: Hartstichting Wetenschapsprijs, Knight of the Order of the Netherlands Lion

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 626

Date

Title

Authors

2020-04-03

Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers - a pre-specified analysis from ORION-1

Ulf Landmesser, John J. P. Kastelein
2020-05-01

Familial Hypercholesterolemia: The Most Common Monogenic Disorder in Humans

John J. P. Kastelein
2020-06-17

Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100,667 Patients

Peter Willeit, Alan Hinderliter, James A. Blumenthal, Andrew Sherwood, Coenraad Dirk Adriaan Stehouwer, John J. P. Kastelein, Peter Reiss
2020-07-01

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial

John J. P. Kastelein
2020-07-22

Lipids and Lipoproteins in 2020

John J. P. Kastelein, Brian A Ference
2020-08-07

Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions

John J. P. Kastelein
2020-08-01

Evinacumab for Homozygous Familial Hypercholesterolemia

Laurens F Reeskamp, John J. P. Kastelein
2020-08-25

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative

David A Fraser, John J. P. Kastelein
2020-07-25

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial

John J. P. Kastelein
2020-08-29

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia

Raul D Santos, Laurens F Reeskamp, Albert Wiegman, John J. P. Kastelein
2020-10-13

Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction

Michał Tendera, Christoph Bode, A Michael Lincoff, John J. P. Kastelein, John H. Alexander, Paul Ridker
2020-09-01

Corrigendum to "Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia" J Clin Lipidol 11 (2017) 1338-1346

John J. P. Kastelein
2020-11-15

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial

A Michael Lincoff, Steven Nissen, John J. P. Kastelein, Dariush Mozaffarian, Christie M. Ballantyne, Paul Ridker
2020-03-18

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Kausik K Ray, John J. P. Kastelein
2020-03-18

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Kausik K Ray, John J. P. Kastelein
2019-10-17

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

Michael G Collins, Ulf Landmesser, John J. P. Kastelein
2019-03-01

Moving Targets: Recent Advances in Lipid-Lowering Therapies

Adriaan G Holleboom, John J. P. Kastelein
2019-10-14

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses

Marja-Riitta Taskinen, John J. P. Kastelein
2019-01-01

Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease

Stephen Nicholls, Alberico L. Catapano, John Danesh, John J. P. Kastelein, Brian A Ference
2019-10-11

Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles

Brant Hubbard, John J. P. Kastelein
2019-04-01

Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial

Stephen Nicholls, A Michael Lincoff, Steven Nissen, John J. P. Kastelein
2019-03-01

Mendelian Randomization Study of ACLY and Cardiovascular Disease

Stephen Nicholls, John Danesh, John J. P. Kastelein, Brian A Ference
2019-10-01

20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia

Albert Wiegman, John J. P. Kastelein
2019-12-05

[Gene Therapy Office; the Potemkin village of the Ministry of Infrastructure and Water Management]

John J. P. Kastelein
2019-09-25

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial

Ulf Landmesser, John J. P. Kastelein
2018-09-28

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial

Stephen Nicholls, Kausik K Ray, Paul Ridker, A Michael Lincoff, Steven Nissen, John J. P. Kastelein, Dariush Mozaffarian, Christie M. Ballantyne
2018-08-29

Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study

John J. P. Kastelein, Kay-Tee Khaw
2018-11-16

FISHing for the Miracle of Eicosapentaenoic Acid

John J. P. Kastelein
2018-11-28

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Lawrence A Leiter, Ulf Landmesser, John J. P. Kastelein
2018-09-01

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1

Kausik K Ray, Ulf Landmesser, John J. P. Kastelein
2018-10

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Frederick J Raal, Mafalda Bourbon, Carolyn Lam, Hapizah M. Nawawi, Maciej Banach, Anne Tybjærg-Hansen, Jacques Genest jr., Olena Mitchenko, Vincent Maher, Erkin Mirrakhimov, Amirhossein Sahebkar, Winfried März, Tomáš Freiberger, Alberico L. Catapano, Heribert Schunkert, Børge G. Nordestgaard, Gerald Watts, John J. P. Kastelein, G Kees Hovingh, Carlos Alberto Aguilar Salinas, Olivier S Descamps, Eric Bruckert
2018-10-01

Effect of Evolocumab on Coronary Plaque Composition

Stephen Nicholls, Steven Nissen, John J. P. Kastelein, Christie M. Ballantyne

Human - wd:Q110410211

Welcome to Inventaire

the library of your friends and communities

learn more